BlackRock, Inc. 13D and 13G filings for Sorrento Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-03-08 2:19 pm Sale |
2023-02-28 | 13G | Sorrento Therapeutics, Inc. SRNE |
BLACKROCK INC BLK |
75,749 0.000% |
-39,347,892 (-99.81%) |
Filing |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | Sorrento Therapeutics, Inc. SRNE |
BLACKROCK INC BLK |
39,423,641 8.400% |
17,647,776 (+81.04%) |
Filing |
| 2022-02-07 4:40 pm Purchase |
2021-12-31 | 13G | Sorrento Therapeutics, Inc. SRNE |
BLACKROCK INC BLK |
21,775,865 6.900% |
4,156,187 (+23.59%) |
Filing |
| 2021-02-02 3:13 pm Purchase |
2020-12-31 | 13G | Sorrento Therapeutics, Inc. SRNE |
BLACKROCK INC BLK |
17,619,678 6.700% |
8,829,581 (+100.45%) |
Filing |